Managing treatment side effects in advanced breast cancer.
OBJECTIVE
To compare and contrast the side-effect profiles of antineoplastic therapy options used in the treatment of metastatic breast cancer.


METHODS
Published research articles, abstracts, and clinical experience.


CONCLUSIONS
Novel and existing antineoplastic agents used in the treatment of metastatic breast cancer generally have mild side effects, but can have the potential for serious reactions. Nausea/vomiting, diarrhea, stomatitis/mucositis, and dermatologic and cardiovascular effects are common. Strategies such as dietary changes, over-the-counter remedies, and dose modification can be used to counteract these mild effects.


CONCLUSIONS
The oncology nurse should be aware of common adverse events associated with antineoplastic agents, recognize early side-effect signs, and be ready with effective strategies to mitigate side effects when and if they occur.
Moore
Susan
S
CancerExpertise, Chicago, IL 60641-3228, USA. susan.moore@cancerexpertise.com
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000628:therapy; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology / Q000628:therapy*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D012871:Skin Diseases / Q000139:chemically induced / Q000628:therapy; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab